Results 181 to 190 of about 67,641 (348)

RAP80 Acts Independently of BRCA1 in Repair of Topoisomerase II Poison-Induced DNA Damage [PDF]

open access: bronze, 2010
Junko Iijima   +3 more
openalex   +1 more source

Caenorhabditis elegans as an in vivo model system for human inherited primary arrhythmia syndromes

open access: yesThe Journal of Physiology, EarlyView.
Abstract figure legend Most genes involved in inherited primary arrhythmia syndromes (IPAS) are conserved in Caenorhabditis elegans, where genetic manipulation enables functional characterization of variants, identification of regulatory proteins, and in vivo drug testing.
Antoine Delinière   +6 more
wiley   +1 more source

Tricyclic 1,5-naphthyridinone oxabicyclooctane-linked novel bacterial topoisomerase inhibitors as broad-spectrum antibacterial agents-SAR of left-hand-side moiety (Part-2)

open access: green, 2015
Sheo B. Singh   +28 more
openalex   +1 more source

Antiplasmodial Activity and Pharmacokinetic Profiling of Cryptolepine and 2,7‐Dibromocryptolepine With a View to Informing the Design of Novel Antimalarial Cryptolepine Analogues

open access: yesDrug Development Research, Volume 87, Issue 2, April 2026.
ABSTRACT The roots of the climbing shrub Cryptolepis sanguinolenta are traditionally used in West Africa for the treatment of malaria. The principal constituent, cryptolepine (1), has been shown to have antimalarial activity but there are concerns regarding its toxicity on account of its DNA‐intercalating property.
Elodie Chenu   +7 more
wiley   +1 more source

Clinical validation of a DNA methylation biomarker associated with overall survival of relapsed ovarian cancer patients

open access: yesInternational Journal of Cancer, Volume 158, Issue 7, Page 1821-1835, 1 April 2026.
What's new? Most patients with ovarian cancer (OC) relapse after first‐line chemotherapy, and prognosis with second‐line treatment depends largely on the platinum‐free interval. However, reliable biomarkers to predict response to second‐line therapy remain lacking.
Muhammad Habiburrahman   +7 more
wiley   +1 more source

Integrated Population Pharmacokinetic, Pharmacodynamic, and Safety Analyses to Inform Dosage Selection in the Clinical Development of the ATR Inhibitor Tuvusertib

open access: yesClinical Pharmacology &Therapeutics, Volume 119, Issue 3, Page 618-628, March 2026.
We present model‐informed selection of the recommended dose for expansion (RDE) of investigational oral ATR inhibitor tuvusertib, by integrating clinical pharmacokinetics (PK), pharmacodynamics (PD), and safety data from DDRiver Solid Tumors 301 trial Part A1 (NCT04170153).
Jatinder Kaur Mukker   +20 more
wiley   +1 more source

Is Micronucleus Assay a Suitable Biomarker for Evaluating the Cancer Risk in Professionals Exposed to Antineoplastic Drugs? A Systematic Review

open access: yesJournal of Applied Toxicology, Volume 46, Issue 3, Page 733-753, March 2026.
ABSTRACT The widespread use of antineoplastic drugs in cancer treatment has led to significant concerns regarding the potential health risks posed to healthcare professionals involved in the preparation, administration, and handling of these chemical compounds, including genotoxicity.
Thiago Guedes Pinto   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy